Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2017

07.09.2017 | Letter to the Editor

Optimism and the continued promise of maintenance chemotherapy

verfasst von: John P. Micha, Bram Goldstein, Maurie Markman

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

Advanced stage ovarian cancer is associated with a high incidence of disease progression and an overall 5-year survival rate of approximately 35% [1]. Patients who obtain a clinical remission in response to debulking surgery and induction platinum-based chemotherapy are regarded as chemo-sensitive and the extent to which they exhibit a sustained platinum free interval favorably impacts their outcome [2, 3]. Therefore, one may assert that strategies which further conduce the platinum free survival will accord a significant, therapeutic benefit. …
Literatur
1.
Zurück zum Zitat Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16:928–36CrossRefPubMedPubMedCentral Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16:928–36CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Colombo N (2014) Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC Suppl 12:7–12CrossRefPubMed Colombo N (2014) Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC Suppl 12:7–12CrossRefPubMed
3.
Zurück zum Zitat Markman M (2015) Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev 34:11–17CrossRefPubMed Markman M (2015) Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev 34:11–17CrossRefPubMed
4.
Zurück zum Zitat Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–2465CrossRefPubMed Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–2465CrossRefPubMed
5.
Zurück zum Zitat Makris EA, MacBarb R, Harvey DJ, Poultsides GA (2017) Surrogate end points for overall survival in metastatic, locally advanced, or unresectable pancreatic cancer: a systematic review and meta-analysis of 24 randomized controlled trials. Ann Surg Oncol 24:2371–2378CrossRefPubMed Makris EA, MacBarb R, Harvey DJ, Poultsides GA (2017) Surrogate end points for overall survival in metastatic, locally advanced, or unresectable pancreatic cancer: a systematic review and meta-analysis of 24 randomized controlled trials. Ann Surg Oncol 24:2371–2378CrossRefPubMed
6.
Zurück zum Zitat Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncoloy Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195–198CrossRefPubMedPubMedCentral Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncoloy Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195–198CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang H, Cella D et al. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study. 2017 Society of Gynecologic Oncology Annual Meeting; National Harbor: Maryland Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang H, Cella D et al. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study. 2017 Society of Gynecologic Oncology Annual Meeting; National Harbor: Maryland
8.
Zurück zum Zitat Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM et al (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115:1028–1035CrossRefPubMedPubMedCentral Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM et al (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115:1028–1035CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Micha JP, Goldstein BH, Rettenmaier MA, Brown JV 3rd, John CR, Markman M (2009) Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer 19:239–241CrossRefPubMed Micha JP, Goldstein BH, Rettenmaier MA, Brown JV 3rd, John CR, Markman M (2009) Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer 19:239–241CrossRefPubMed
10.
Zurück zum Zitat Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL et al (2017) Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol 80:405–410CrossRefPubMed Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL et al (2017) Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol 80:405–410CrossRefPubMed
11.
Zurück zum Zitat Zhang T, Pan Q, Xiao S, Li L, Xue M (2016) Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer. Oncol Lett 11:3287–3292PubMedPubMedCentral Zhang T, Pan Q, Xiao S, Li L, Xue M (2016) Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer. Oncol Lett 11:3287–3292PubMedPubMedCentral
12.
Zurück zum Zitat Colombo N, Lorusso D, Scollo P (2017) Impact of recurrence of ovarian cancer on quality of life and outlook for the future. Int J Gynecol Cancer 27:1134–1140CrossRefPubMedPubMedCentral Colombo N, Lorusso D, Scollo P (2017) Impact of recurrence of ovarian cancer on quality of life and outlook for the future. Int J Gynecol Cancer 27:1134–1140CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M et al (2017) Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach. Gynecol Oncol 146:101–108CrossRefPubMed Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M et al (2017) Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach. Gynecol Oncol 146:101–108CrossRefPubMed
14.
Zurück zum Zitat Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75–87CrossRefPubMed Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75–87CrossRefPubMed
Metadaten
Titel
Optimism and the continued promise of maintenance chemotherapy
verfasst von
John P. Micha
Bram Goldstein
Maurie Markman
Publikationsdatum
07.09.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3428-0

Weitere Artikel der Ausgabe 4/2017

Cancer Chemotherapy and Pharmacology 4/2017 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.